Giuseppe M.C. Rosano, John R. Teerlink, Koichiro Kinugawa, Antoni Bayes-Genis, Ovidiu Chioncel, James Fang, Barry Greenberg, Nasrien E. Ibrahim, Teruhiko Imamura, Takayuki Inomata, Koichiro Kuwahara, Brenda Moura, Anekwe Onwuanyi, Naoki Sato, Gianluigi Savarese, Yasuhiko Sakata, Nancy Sweitzer, Jane Wilcox, Kazuhiro Yamamoto, Marco Metra, Andrew J.S. Coats
This clinical consensus statement revisits the role of left ventricular ejection fraction (LVEF) as a measurement of cardiac function, a prognostic marker and a major criterion to classify patients with heart failure, and gives new advice for clinical practice. Heart failure is traditionally classified on the basis of LVEF thresholds and this has major implications for treatment recommendations. However, the reproducibility of LVEF measurement is poor and its prognostic and diagnostic value lessens when it is above 45%, with no relationship with the severity of either cardiac dysfunction or outcomes at higher values. These limitations dictate the need for a more comprehensive approach to classify and assess heart failure focusing more on the trajectory of LVEF rather than to its absolute value. Furthermore, the assessment of LVEF is not required for the initiation of treatments like sodium–glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists and diuretics in patients with suspected de novo heart failure and elevated N-terminal pro-B-type natriuretic peptide levels. Future research utilizing advanced imaging techniques and biomarkers which can better characterize myocardial structure, metabolism and performance may facilitate the identification of alternative therapeutic targets and better ways to monitor heart failure therapies across the entire spectrum of LVEF.
{"title":"The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)","authors":"Giuseppe M.C. Rosano, John R. Teerlink, Koichiro Kinugawa, Antoni Bayes-Genis, Ovidiu Chioncel, James Fang, Barry Greenberg, Nasrien E. Ibrahim, Teruhiko Imamura, Takayuki Inomata, Koichiro Kuwahara, Brenda Moura, Anekwe Onwuanyi, Naoki Sato, Gianluigi Savarese, Yasuhiko Sakata, Nancy Sweitzer, Jane Wilcox, Kazuhiro Yamamoto, Marco Metra, Andrew J.S. Coats","doi":"10.1002/ejhf.3646","DOIUrl":"https://doi.org/10.1002/ejhf.3646","url":null,"abstract":"This clinical consensus statement revisits the role of left ventricular ejection fraction (LVEF) as a measurement of cardiac function, a prognostic marker and a major criterion to classify patients with heart failure, and gives new advice for clinical practice. Heart failure is traditionally classified on the basis of LVEF thresholds and this has major implications for treatment recommendations. However, the reproducibility of LVEF measurement is poor and its prognostic and diagnostic value lessens when it is above 45%, with no relationship with the severity of either cardiac dysfunction or outcomes at higher values. These limitations dictate the need for a more comprehensive approach to classify and assess heart failure focusing more on the trajectory of LVEF rather than to its absolute value. Furthermore, the assessment of LVEF is not required for the initiation of treatments like sodium–glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists and diuretics in patients with suspected de novo heart failure and elevated N-terminal pro-B-type natriuretic peptide levels. Future research utilizing advanced imaging techniques and biomarkers which can better characterize myocardial structure, metabolism and performance may facilitate the identification of alternative therapeutic targets and better ways to monitor heart failure therapies across the entire spectrum of LVEF.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"25 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jawad H. Butt, Scott D. Solomon, Muthiah Vaduganathan, Dirk J. van Veldhuisen, Lars Køber, Bertram Pitt, Faiez Zannad, Pardeep S. Jhund, John J.V McMurray
Obesity is associated with excessive adipocyte-derived aldosterone secretion, independent of the classical renin–angiotensin–aldosterone cascade, and mineralocorticoid receptor antagonists (MRAs) may be more effective in obese patients with heart failure (HF) with reduced ejection fraction (HFrEF).
{"title":"Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction according to body weight","authors":"Jawad H. Butt, Scott D. Solomon, Muthiah Vaduganathan, Dirk J. van Veldhuisen, Lars Køber, Bertram Pitt, Faiez Zannad, Pardeep S. Jhund, John J.V McMurray","doi":"10.1002/ejhf.3665","DOIUrl":"https://doi.org/10.1002/ejhf.3665","url":null,"abstract":"Obesity is associated with excessive adipocyte-derived aldosterone secretion, independent of the classical renin–angiotensin–aldosterone cascade, and mineralocorticoid receptor antagonists (MRAs) may be more effective in obese patients with heart failure (HF) with reduced ejection fraction (HFrEF).","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"29 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143853105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sebastiaan Dhont, Philippe B. Bertrand, Jonas Erzeel, Sébastien Deferm, Laurent Pison, Pieter M. Vandervoort, Wilfried Mullens, W.H. Wilson Tang, Pieter Martens
Atrial fibrillation (AF) and mitral regurgitation (MR) frequently coexist. While catheter ablation is a key rhythm-control strategy in AF, its impact on MR severity remains uncertain. This study evaluates the effects of catheter ablation on AF recurrence, functional status, and MR progression in patients with AF and baseline MR.
{"title":"The interaction between atrial fibrillation and mitral regurgitation: Insights from the CABANA randomized clinical trial","authors":"Sebastiaan Dhont, Philippe B. Bertrand, Jonas Erzeel, Sébastien Deferm, Laurent Pison, Pieter M. Vandervoort, Wilfried Mullens, W.H. Wilson Tang, Pieter Martens","doi":"10.1002/ejhf.3668","DOIUrl":"https://doi.org/10.1002/ejhf.3668","url":null,"abstract":"Atrial fibrillation (AF) and mitral regurgitation (MR) frequently coexist. While catheter ablation is a key rhythm-control strategy in AF, its impact on MR severity remains uncertain. This study evaluates the effects of catheter ablation on AF recurrence, functional status, and MR progression in patients with AF and baseline MR.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"67 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143853098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuxiang Luo, Wenbin Xiao, Yusuf Z. Sener, Wouter C. Meijers, Robert M.A. van der Boon, Elfatih A. Hasabo, Osama Soliman, Rudolf A. de Boer, Kadir Caliskan
The necessity of lifelong treatment and polypharmacy in chronic heart failure (HF) patients with improved myocardial function remains debated. This systematic review aims to synthesize current literature regarding this issue.
{"title":"Minimization or withdrawal of oral pharmacotherapy in chronic heart failure patients with improved myocardial function: A systematic review","authors":"Yuxiang Luo, Wenbin Xiao, Yusuf Z. Sener, Wouter C. Meijers, Robert M.A. van der Boon, Elfatih A. Hasabo, Osama Soliman, Rudolf A. de Boer, Kadir Caliskan","doi":"10.1002/ejhf.3652","DOIUrl":"https://doi.org/10.1002/ejhf.3652","url":null,"abstract":"The necessity of lifelong treatment and polypharmacy in chronic heart failure (HF) patients with improved myocardial function remains debated. This systematic review aims to synthesize current literature regarding this issue.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"29 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143853109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The clinical guidelines categorize heart failure (HF) based on left ventricular ejection fraction (LVEF). However, the current LVEF cutoffs, 40% and 50%, may not fully address the underlying characteristics and cardiovascular risk of HF, particularly for HF with higher LVEF. This study aimed to characterize HF with supranormal ejection fraction (HFsnEF) using different LVEF cutoffs (35%, 55%, and 70% for men, and 40%, 60%, and 75% for women).
{"title":"Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure","authors":"Yasuhiko Sakata, Kotaro Nochioka, Satoshi Yasuda, Koichi Ishida, Takashi Shiroto, Jun Takahashi, Shintaro Kasahara, Ruri Abe, Shinsuke Yamanaka, Takahide Fujihashi, Hideka Hayashi, Shintaro Kato, Katsunori Horii, Kanako Teramoto, Tsutomu Tomita, Satoshi Miyata, Koichiro Sugimura, Iwao Waga, Masao Nagasaki, Hiroaki Shimokawa","doi":"10.1002/ejhf.3654","DOIUrl":"https://doi.org/10.1002/ejhf.3654","url":null,"abstract":"The clinical guidelines categorize heart failure (HF) based on left ventricular ejection fraction (LVEF). However, the current LVEF cutoffs, 40% and 50%, may not fully address the underlying characteristics and cardiovascular risk of HF, particularly for HF with higher LVEF. This study aimed to characterize HF with supranormal ejection fraction (HFsnEF) using different LVEF cutoffs (35%, 55%, and 70% for men, and 40%, 60%, and 75% for women).","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"38 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143832016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antoni Bayes-Genis, Lisa Anderson, Ed Harding, Marco Metra, John R. Teerlink, James L. Januzzi, Javed Butler, Giuseppe M.C. Rosano
Click on the article title to read more.
{"title":"Late diagnosis in cancer sparks outrage—so why not heart failure?","authors":"Antoni Bayes-Genis, Lisa Anderson, Ed Harding, Marco Metra, John R. Teerlink, James L. Januzzi, Javed Butler, Giuseppe M.C. Rosano","doi":"10.1002/ejhf.3667","DOIUrl":"https://doi.org/10.1002/ejhf.3667","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"25 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143832017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Katharina Mueller, Markus F. Scheerer, Prabhakar Viswanathan, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray
AimsChronic obstructive pulmonary disease (COPD) is associated with worse outcomes in heart failure (HF) with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). A post hoc analysis of TOPCAT suggested that the effectiveness of the steroidal mineralocorticoid receptor antagonist (MRA), spironolactone, may be modified by pulmonary disease, with a greater benefit in patients with COPD/asthma. We examined the effects of the non‐steroidal MRA, finerenone, compared to placebo, according to COPD status in a prespecified analysis of FINEARTS‐HF.Methods and resultsA history of COPD was investigator‐reported. The primary outcome was the composite of cardiovascular death and total worsening HF events. Of the 6001 patients randomized in FINEARTS‐HF, 773 patients (12.9%) had COPD. Compared to patients without COPD, those with COPD had more adverse clinical features, including worse New York Heart Association class and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, more prior HF hospitalization, atrial fibrillation/flutter, obesity, peripheral artery disease, and hypertension, as well as elevated high‐sensitivity troponin T levels. Patients with COPD had a higher risk of the primary endpoint (adjusted rate ratio [RR] 1.44, 95% confidence interval [CI] 1.21–1.71). The benefit of finerenone on the primary outcome was consistent irrespective of COPD status (no COPD: RR 0.84 [95% CI 0.73–0.97]; COPD: 0.84 [95% CI 0.61–1.16]; pinteraction = 0.93). Consistent effects were also observed for all secondary outcomes. Finerenone improved KCCQ total symptom score from baseline to 12 months to a similar extent in patients with and without COPD (pinteraction = 0.46).ConclusionIn patients with HFmrEF/HFpEF, the beneficial effects of finerenone on clinical events and symptoms were consistent, regardless of COPD status.Clinical Trial Registration: ClinicalTrials.gov ID NCT04435626.
{"title":"Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial","authors":"Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Katharina Mueller, Markus F. Scheerer, Prabhakar Viswanathan, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray","doi":"10.1002/ejhf.3661","DOIUrl":"https://doi.org/10.1002/ejhf.3661","url":null,"abstract":"AimsChronic obstructive pulmonary disease (COPD) is associated with worse outcomes in heart failure (HF) with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). A post hoc analysis of TOPCAT suggested that the effectiveness of the steroidal mineralocorticoid receptor antagonist (MRA), spironolactone, may be modified by pulmonary disease, with a greater benefit in patients with COPD/asthma. We examined the effects of the non‐steroidal MRA, finerenone, compared to placebo, according to COPD status in a prespecified analysis of FINEARTS‐HF.Methods and resultsA history of COPD was investigator‐reported. The primary outcome was the composite of cardiovascular death and total worsening HF events. Of the 6001 patients randomized in FINEARTS‐HF, 773 patients (12.9%) had COPD. Compared to patients without COPD, those with COPD had more adverse clinical features, including worse New York Heart Association class and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, more prior HF hospitalization, atrial fibrillation/flutter, obesity, peripheral artery disease, and hypertension, as well as elevated high‐sensitivity troponin T levels. Patients with COPD had a higher risk of the primary endpoint (adjusted rate ratio [RR] 1.44, 95% confidence interval [CI] 1.21–1.71). The benefit of finerenone on the primary outcome was consistent irrespective of COPD status (no COPD: RR 0.84 [95% CI 0.73–0.97]; COPD: 0.84 [95% CI 0.61–1.16]; <jats:italic>p</jats:italic><jats:sub>interaction</jats:sub> = 0.93). Consistent effects were also observed for all secondary outcomes. Finerenone improved KCCQ total symptom score from baseline to 12 months to a similar extent in patients with and without COPD (<jats:italic>p</jats:italic><jats:sub>interaction</jats:sub> = 0.46).ConclusionIn patients with HFmrEF/HFpEF, the beneficial effects of finerenone on clinical events and symptoms were consistent, regardless of COPD status.Clinical Trial Registration: ClinicalTrials.gov ID NCT04435626.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"112 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143827303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eva Del Mestre, Alessia Paldino, Carola Pio Loco Detto Gava, Ilaria Gandin, Marta Gigli, Davide Stolfo, Martina Setti, Giovanni Maria Severini, Beatrice Spedicati, Stefania Lenarduzzi, Giorgia Girotto, Alessandro Folgheraiter, Jacopo Giulio Rizzi, Renata Korcova, Luisa Mestroni, Marco Merlo, Matteo Dal Ferro, Gianfranco Sinagra
AimsThe prognostic significance of detecting left ventricular (LV) systolic dysfunction during family screening programmes (FSPs) in relatives of probands affected by dilated (DCM) and non‐dilated left ventricular (NDLVC) cardiomyopathies remain unclear. This study sought to evaluate the prognostic role of LV systolic dysfunction detection in relatives of DCM/NDLVC probands and to define the most accurate FSP.Methods and resultsBaseline and follow‐up data of first‐degree relatives of probands affected by DCM/NDLVC were collected. The primary outcome was all‐cause death and heart transplantation. Secondary heart failure (HF) and arrhythmic outcomes were also included. A total of 492 first degree relatives were enrolled. During a median follow‐up of 110 months (interquartile range 57–188 months), only subjects that previously developed LV systolic dysfunction had primary outcomes (19 vs. 0, p < 0.001) and secondary outcomes (HF: 12 vs. 0, p = 0.005; arrhythmic: 30 vs. 0, p < 0.001). Subjects with LV systolic dysfunction detected by FSP showed lower rate of primary outcomes (FSP: n = 19 [14%]; no‐FSP: n = 40 [37%]; p < 0.001) and secondary arrhythmic outcomes (FSP: n = 18 [13%]; no‐FSP: n = 41 [38%]; p < 0.001). In this setting, family history of arrhythmia and being carrier of a pathogenic/likely pathogenic variant are the main risk factors for LV systolic dysfunction, while LV global longitudinal strain (LV‐GLS) and Holter electrocardiogram (ECG) showed a relevant role in terms of prediction of LV systolic dysfunction and outcomes.ConclusionRelatives of DCM/NDLVC probands who developed LV systolic dysfunction during a long follow‐up had a significant increased risk of major adverse cardiovascular outcomes. However, LV systolic dysfunction detected by FSP showed a better prognosis. In this context, genetics, Holter ECG and LV‐GLS demonstrated their functional role for disease and event prediction.
{"title":"Prediction and prognostic role of left ventricular systolic dysfunction in family screening for dilated cardiomyopathy and non‐dilated left ventricular cardiomyopathy","authors":"Eva Del Mestre, Alessia Paldino, Carola Pio Loco Detto Gava, Ilaria Gandin, Marta Gigli, Davide Stolfo, Martina Setti, Giovanni Maria Severini, Beatrice Spedicati, Stefania Lenarduzzi, Giorgia Girotto, Alessandro Folgheraiter, Jacopo Giulio Rizzi, Renata Korcova, Luisa Mestroni, Marco Merlo, Matteo Dal Ferro, Gianfranco Sinagra","doi":"10.1002/ejhf.3657","DOIUrl":"https://doi.org/10.1002/ejhf.3657","url":null,"abstract":"AimsThe prognostic significance of detecting left ventricular (LV) systolic dysfunction during family screening programmes (FSPs) in relatives of probands affected by dilated (DCM) and non‐dilated left ventricular (NDLVC) cardiomyopathies remain unclear. This study sought to evaluate the prognostic role of LV systolic dysfunction detection in relatives of DCM/NDLVC probands and to define the most accurate FSP.Methods and resultsBaseline and follow‐up data of first‐degree relatives of probands affected by DCM/NDLVC were collected. The primary outcome was all‐cause death and heart transplantation. Secondary heart failure (HF) and arrhythmic outcomes were also included. A total of 492 first degree relatives were enrolled. During a median follow‐up of 110 months (interquartile range 57–188 months), only subjects that previously developed LV systolic dysfunction had primary outcomes (19 vs. 0, <jats:italic>p</jats:italic> < 0.001) and secondary outcomes (HF: 12 vs. 0, <jats:italic>p</jats:italic> = 0.005; arrhythmic: 30 vs. 0, <jats:italic>p</jats:italic> < 0.001). Subjects with LV systolic dysfunction detected by FSP showed lower rate of primary outcomes (FSP: <jats:italic>n</jats:italic> = 19 [14%]; no‐FSP: <jats:italic>n</jats:italic> = 40 [37%]; <jats:italic>p</jats:italic> < 0.001) and secondary arrhythmic outcomes (FSP: <jats:italic>n</jats:italic> = 18 [13%]; no‐FSP: <jats:italic>n</jats:italic> = 41 [38%]; <jats:italic>p</jats:italic> < 0.001). In this setting, family history of arrhythmia and being carrier of a pathogenic/likely pathogenic variant are the main risk factors for LV systolic dysfunction, while LV global longitudinal strain (LV‐GLS) and Holter electrocardiogram (ECG) showed a relevant role in terms of prediction of LV systolic dysfunction and outcomes.ConclusionRelatives of DCM/NDLVC probands who developed LV systolic dysfunction during a long follow‐up had a significant increased risk of major adverse cardiovascular outcomes. However, LV systolic dysfunction detected by FSP showed a better prognosis. In this context, genetics, Holter ECG and LV‐GLS demonstrated their functional role for disease and event prediction.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"5 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143827304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Andrea Lage, Katja Rohwedder, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray
The efficacy and safety of the non-steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients without diabetes. We examined the efficacy and safety of finerenone, compared with placebo, according to glycaemic status in FINEARTS-HF.
{"title":"Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial","authors":"Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Andrea Lage, Katja Rohwedder, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray","doi":"10.1002/ejhf.3649","DOIUrl":"https://doi.org/10.1002/ejhf.3649","url":null,"abstract":"The efficacy and safety of the non-steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients without diabetes. We examined the efficacy and safety of finerenone, compared with placebo, according to glycaemic status in FINEARTS-HF.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"22 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Biykem Bozkurt, Wilfried Mullens, Christophe Leclercq, Andrea M. Russo, Gianluigi Savarese, Michael Böhm, Loreena Hill, Koichiro Kinugawa, Naoki Sato, William T. Abraham, Antoni Bayes‐Genis, Alexandre Mebazaa, Giuseppe M.C. Rosano, Shelley Zieroth, Cecilia Linde, Javed Butler
Guidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision‐making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices are frequently referred too late or not at all. Misconceptions about device therapy and the notion that the needs of patients (especially the prevention of sudden cardiac death) can now be met by expanding drug therapies may play a role in these disparities. This state‐of‐the‐art review is produced by members of the DIRECT HF initiative, a patient‐centred, expert‐led educational programme that aims to advance guideline‐directed use of CRM devices in patients with HFrEF. This review discusses the latest evidence on the role of CRM devices in reducing HFrEF mortality and morbidity, and provides practical guidance on patient referral, device selection, implant timing and patient‐centred follow‐up.
{"title":"Cardiac rhythm devices in heart failure with reduced ejection fraction – role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document","authors":"Biykem Bozkurt, Wilfried Mullens, Christophe Leclercq, Andrea M. Russo, Gianluigi Savarese, Michael Böhm, Loreena Hill, Koichiro Kinugawa, Naoki Sato, William T. Abraham, Antoni Bayes‐Genis, Alexandre Mebazaa, Giuseppe M.C. Rosano, Shelley Zieroth, Cecilia Linde, Javed Butler","doi":"10.1002/ejhf.3641","DOIUrl":"https://doi.org/10.1002/ejhf.3641","url":null,"abstract":"Guidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision‐making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices are frequently referred too late or not at all. Misconceptions about device therapy and the notion that the needs of patients (especially the prevention of sudden cardiac death) can now be met by expanding drug therapies may play a role in these disparities. This state‐of‐the‐art review is produced by members of the DIRECT HF initiative, a patient‐centred, expert‐led educational programme that aims to advance guideline‐directed use of CRM devices in patients with HFrEF. This review discusses the latest evidence on the role of CRM devices in reducing HFrEF mortality and morbidity, and provides practical guidance on patient referral, device selection, implant timing and patient‐centred follow‐up.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"59 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143813520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：